HUBEI PROVINCE, China--(BUSINESS WIRE)--Benda Pharmaceutical, Inc. (“Benda” or the “Company”) (OTCBB: BPMA), a China-based pharmaceutical company producing both Gendicine®, the world’s first commercialized gene therapy medicine for the treatment of cancer, and traditional Chinese and conventional medicines, announced today that its Jiangling plant has received approval from the State Food and Drug Administration (“SFDA”) to reinitiate production of its primary product line. This was the last step necessary for Jiangling to be eligible for Good Manufacturing Practices (“GMP”) certification, a standard required in China to produce pharmaceuticals or their ingredients. Jiangling will begin production immediately upon the receipt of its GMP certification.
